Portfolio reviews in clinical operations are often an exercise in reconciliation rather than decision-making. Clinical operations teams arrive with CTMS dashboards focused on enrollment, site startup, and data quality. Finance teams bring ERP-based views of budget burn, accruals, and cash flow. Site-payment teams reference their own trackers or vendor portals.
The result? Leaders spend significant time and energy on translation, answering basic questions like Which studies are healthy? Which are financially risky? Where do we need to intervene? before any real decisions can be made.
For Cloudbyz customers, a better approach is available: a concise, shared set of CTMS-based financial health metrics that serves as the single starting point for portfolio reviews.
Rather than maintaining separate KPI frameworks for operations and finance, organizations can build a unified framework on top of CTMS events and Cloudbyz CTFM logic. This means:
Industry analysis supports this direction. Trialonic's research on real-time clinical trial dashboards emphasizes that effective views must integrate operational and financial data. Similarly, planning-focused resources from vendors like Anaplan highlight that portfolio decisions are strongest when grounded in shared drivers rather than siloed reports.
When designed this way, a portfolio review dashboard presents operational tiles (startup readiness, enrollment vs. plan, verified-visit coverage, deviation trends) directly alongside financial tiles (budget burn, accrual coverage, payment SLAs, and risk scores). When something is off, everyone sees it in the same place and drills into the same evidence.
Designing CTMS dashboards for financial health means more than adding currency symbols to existing operational tiles. It requires a small, opinionated set of metrics that portfolio leaders can interpret quickly and investigate when needed.
To answer these questions, Cloudbyz can expose the following metrics:
Effective dashboards translate these metrics into clear, actionable visuals:
Dashboards should also expose signals that reveal whether financial views can be trusted. Metrics to watch include:
When data quality slips, Cloudbyz can route tasks back to study teams before inaccurate numbers reach board decks or SEC filings.
Even the best metrics lose impact without consistent use. Embedding CTMS financial health views into regular governance rhythms is what transforms them from reporting artifacts into genuine control mechanisms.
A monthly review is the right center of gravity for most organizations. Leaders review a portfolio grid showing each program's operational and financial health tiles side by side. When a tile turns amber or red, the conversation focuses on drivers and actions:
Quarterly, these views feed rolling forecasts and scenario planning. Because Cloudbyz KPIs are grounded in CTMS events, scenarios can be expressed in operational terms (more sites, different geographies, alternate visit patterns) rather than only in budget lines.
CTMS-based financial health views should also inform the organization's external narrative. When boards, investors, or partners ask how trials are performing, leaders can reference the same high-level tiles they review every month, explaining variances in terms of CTMS drivers and CTFM rules rather than generic financial abstractions. Over time, this consistency builds trust by demonstrating that internal oversight and external communication are built on the same foundation.
Metrics only remain credible if they are actively maintained. Treat CTMS KPIs as governed products:
When these practices are in place, CTMS financial health metrics stop being "one more dashboard" and become the default language of portfolio reviews, a shared vocabulary that accelerates decisions and builds organizational confidence in clinical trial data.